ClinicalTrials.gg
CompletedNCT06592274HB0017Updated Oct 23, 2026

A Phase 2 Study of HB0017 in Psoriasis Patients

A Phase 2 interventional study of HB0017 and HB0017 in Psoriasis (PsO), sponsored by Huabo Biopharm Co., Ltd.. Completed at 18 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Huabo Biopharm Co., Ltd. · Phase 2, Interventional, and Treatment

Updated Oct 23, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
206
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Enrollment
80th of 182
206 · median 171
Started
2024
with 24 others
Phase 2
42 of 206
11 open now
Registered
141st of 206
by date
Lead sponsor
5 of 206
Huabo Biopharm Co., Ltd.

Among the 206 studies in Psoriasis with a site in China, this one is the 80th largest by enrollment of the 182 interventional ones that give a count, is one of 25 that started in 2024, is one of 42 in phase 2, and was the 141st registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque psoriasis in subjects

03

Conditions studied

  • Psoriasis (PsO)

Browse trials for

Keywords

  • HB0017
  • psoriasis
  • longer dose regimen
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged 18-75 years (inclusive)
  • Chronic plaque psoriasis (PSO) for at least 6 months prior to the randomization.
  • Psoriasis Area Severity Index (PASI) \>=12 and body surface area (BSA) affected by PSO \>=10% and Static Physician Global Assessment (sPGA) score \>=3.
  • Subjects who are suitable for systemic treatment or phototherapy for psoriasis as judged by the investigator
  • Subjects who are able to use effective from the screening period to 6 months after the last dose

Exclusion criteria

Exclusion Criteria:

  • Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and/or guttate psoriasis) at screening or baseline Drug-induced psoriasis
  • Ongoing use of prohibited treatments
  • Any active infection (other than common cold) within 14 days
  • Serious infection defined as requiring hospitalization or iv anti-infective(s) within 1 month prior to randomization
  • Have previously received any drug that directly targets IL-17 or IL-17 receptor
  • Have concurrent or recent use of any biologic agent within the following : etanercept \<28 days; infliximab and adalimumab \<60 days; golimumab \< 90 days; anti-IL-12/anti-IL-23 or anti-IL-23p19 antibody drugs \<6 months; or other anti-psoriatic therapy not listed herein within its 5 half-lives prior to randomization
  • A history of inflammatory bowel disease or other serious disease
  • Previously diagnosed with serious mental illness such as anxiety, depression or suicidal tendency
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
206 participants (actual)

Study arms

  • Experimental
    Experimental Group 1

    HB0017 higer dose plus longer dose regimen

    Biological: HB0017

  • Experimental
    Experimental Group 2

    HB0017 higer dose plus shorter dose regimen

    Biological: HB0017

  • Experimental
    Experimental Group 3

    HB0017 low dose plus shortest dose regimen

    Biological: HB0017

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of subjects achieving PASI 90 response

    The PASI75 response assessments are based on at least 90% improvement in PASI score from Baseline.

    Time frame: Week 12

  2. Proportion of subjects achieving sPGA 0/1

    The sPGA is a physician\&amp;#39;s determination of the participant\&amp;#39;s psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant\&amp;#39;s psoriasis is assessed as clear (0), Almost clear (1), mild (2), moderate (3), severe (4). An sPGA 0/1 response was defined as a post-baseline sPGA score of 0 or 1.

    Time frame: Week 12

Secondary outcomes

  1. Proportion of subjects achieving PASI 75 response

    The PASI75 response assessments are based on at least 75% improvement in PASI score from Baseline.

    Time frame: Week 12

  2. Proportion of subjects achieving PASI 100 response

    The PASI100 response assessments are based on 100% improvement in PASI score from Baseline

    Time frame: Week 12

  3. PASI 90 response maintainance at week 48

    Proportion of subjects maintaining PASI 90 response at Week 48 among those with PASI 90 response at Week 12

    Time frame: Week12-48

  4. sPGA 0/1 response maintainance at week 48

    Proportion of subjects maintaining sPGA 0/1 response at Week 48 among those with sPGA 0/1 response at Week 12.

    Time frame: Week12-48

07

Study locations

18 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui, China
  • Southern Medical University Dermatology Hospital
    Guangzhou, Guangdong, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • Wuxi Second People's Hospital
    Wuxi, Jiangsu, China
  • Jiangsu University Affiliated Hospital
    Zhenjiang, Jiangsu, China
  • Jilin University Second Hospital
    Changchun, Jilin, China
  • Shandong First Medical University Affiliated Dermatology Hospital
    Jinan, Shandong 0531, China
  • Jining First People's Hospital
    Jining, Shandong 0531, China
  • Xingtai People's Hospital
    Xingtai, Shandong 0531, China
  • Shanxi Medical University Second Hospital
    Taiyuan, Shanxi, China
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan, China
  • Chongqing Traditional Chinese Medicine Hospital
    Chongqing, Sichuan, China
  • Hangzhou First People's Hospital
    Hangzhou, Zhejiang, China
  • The First Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Jiaxing First Hospital
    Jiaxing, Zhejiang, China
  • Wenzhou Medical University Affiliated First Hospital
    Wenzhou, Zhejiang, China
  • Guangdong Provincial People's Hospital
    Guangzhou, China
  • Ningbo Second Hospital
    Ningbo, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Apr 2025, 7 months.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 7 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

Completion moved once since we started tracking on Sep 25, 2026: Jan 2026 → Apr 2026, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2024
First posted
Sep 19, 2024
StartActual
Sep 30, 2024
Primary completionActual
Apr 30, 2025
CompletionActual
Apr 10, 2026was Jan 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 23, 2026
Study completion
Jan 30, 2026→Apr 10, 2026 (actual)
Oct 23, 2026
Enrollment
200 (estimated)→206 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Recruiting→Completed
    Study completion Jan 30, 2026→Apr 10, 2026 (now actual)
    Enrollment 200 (estimated)→206 (actual)
    + 4 other changes: verification date, oversight details, site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06592274
Lead sponsor
Huabo Biopharm Co., Ltd.
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 30, 2024
Primary completion
Apr 30, 2025
Completion
Apr 10, 2026
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HB0017

Start the discussion